2019
A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer
Piao X, Jeong P, Yan C, Kim Y, Byun Y, Xu Y, Kang H, Seo S, Kim W, Lee J, Kim I, Moon S, Choi Y, Cha E, Yun S, Kim W. A novel tumor suppressing gene, ARHGAP9, is an independent prognostic biomarker for bladder cancer. Oncology Letters 2019, 19: 476-486. PMID: 31897161, PMCID: PMC6924059, DOI: 10.3892/ol.2019.11123.Peer-Reviewed Original ResearchNon-muscle invasive BCMuscle-invasive BCIndependent prognostic biomarkerInvasive BCPrognostic biomarkerProlonged recurrence-free survivalCancer-specific survivalCancer-specific deathRecurrence-free survivalTissues of patientsBC tissue samplesExpression of mRNAVital clinical significanceMIBC patientsBC prognosisPoor prognosisBladder cancerClinical significanceCancer tumorigenesisUseful markerLow expressionPatientsNovel tumorHigh expressionTissue samples
2018
Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer
Jang T, Patel N, Faiena I, Radadia K, Moore D, Elsamra S, Singer E, Stein M, Eastham J, Scardino P, Lin Y, Kim I, Lu‐Yao G. Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 2018, 124: 4010-4022. PMID: 30252932, PMCID: PMC6234085, DOI: 10.1002/cncr.31726.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen AntagonistsAntineoplastic Agents, HormonalCombined Modality TherapyDisease ProgressionDisease-Free SurvivalFollow-Up StudiesHumansMaleOutcome Assessment, Health CareProstatectomyProstatic NeoplasmsRadiotherapy, AdjuvantSEER ProgramSurvival AnalysisTreatment OutcomeUnited StatesConceptsAndrogen deprivation therapyAdvanced prostate cancerRadical prostatectomyProstate cancerDeprivation therapyOverall survivalUrinary incontinenceErectile dysfunctionProstate cancer-specific survivalProstate cancer-specific deathCox proportional hazards modelCancer-specific survivalCancer-specific deathKaplan-Meier methodSEER-Medicare dataProportional hazards modelDifferent treatment approachesHigh rateAdjuvant radiotherapyTreatment armsSurvival outcomesGleason scoreTumor stageClinical guidelinesHigh risk
2014
Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2
Kim Y, Kim W, Jeong P, Ha Y, Kang H, Yun S, Moon S, Choi Y, Kim I, Kim W. Novel Combination Markers for Predicting Survival in Patients with Muscle Invasive Bladder Cancer: USP18 and DGCR2. Journal Of Korean Medical Science 2014, 29: 351-356. PMID: 24616583, PMCID: PMC3945129, DOI: 10.3346/jkms.2014.29.3.351.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkersCarrier ProteinsEndopeptidasesFemaleGene Expression ProfilingHumansKaplan-Meier EstimateMaleMiddle AgedMuscle NeoplasmsNeoplasm InvasivenessNeoplasm StagingPlatelet Glycoprotein GPIb-IX ComplexPredictive Value of TestsRegression AnalysisRisk FactorsROC CurveUbiquitin ThiolesteraseUrinary Bladder NeoplasmsConceptsCancer-specific survivalCancer-specific deathBladder cancer patientsHigh expression groupExpression of USP18MIBC patientsCancer patientsExpression groupMuscle-invasive bladder cancer patientsCancer-specific survival ratesInvasive bladder cancer patientsMuscle-invasive bladder cancerLonger cancer-specific survivalMultivariate Cox regression analysisCox regression analysisInvasive bladder cancerSignificant risk factorsReliable prognostic markersMRNA expression levelsSurvival-related genesOverall survivalValidation cohortOriginal cohortLonger survivalPredicting Survival